Pyrazolylaminobenzimidazole derivatives as JAK inhibitors
申请人:Eli Lilly and Company
公开号:US10323019B2
公开(公告)日:2019-06-18
The present invention provides compounds of the formula below (I′): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.
PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS
申请人:Eli Lilly and Company
公开号:EP3484875B1
公开(公告)日:2021-04-07
[EN] PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLYLAMINOBENZIMIDAZOLE EN TANT QU'INHIBITEURS DE JAK
申请人:LILLY CO ELI
公开号:WO2018013486A1
公开(公告)日:2018-01-18
The present invention provides compounds of the formula below (I'): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.